Drug intelligence / Profile preview

DC-CIK01

Development stage: Unknown
Lead developer: Ever Supreme Bio-Technology
Modality: Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

**DC-CIK01** is an autologous dendritic cell-cytokine-induced killer cell therapy developed by Ever Supreme Bio Technology for stage IV solid tumors, specifically including breast cancer and colorectal cancer. The product co-cultures dendritic cells with cytokine-induced killer cells and uses Wilms tumor protein 1 peptide to prime dendritic-cell antigen presentation, promoting WT1-directed cytotoxic immune activity against WT1-expressing tumor cells while retaining broader CIK-cell antitumor activity. Ever Supreme describes an approximately two-week DC/CIK co-culture process that can be used without obtaining a patient's tumor tissue. ([en.ever-supreme.com.tw](https://en.ever-supreme.com.tw/products_detail/2/1))

Other names: DC-CIK (WT1)DC-CIK(WT1)Dendritic Cell-Cytokine Induced Killer Cell (WT1)

Targets

WT1 (Wilms tumor protein)

Beyond the preview

Go deeper on DC-CIK01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-CIK01.

Explore the full profile